Michigan State: Collaboration Leads to Promising Next Steps for Cancer Research
September 11, 2020
September 11, 2020
EAST LANSING, Michigan, Sept. 11 (TNSRes) -- Michigan State University issued the following news release:
A cancer research company co-founded by a Michigan State University professor was acquired by the New York biotechnology firm Lodo Therapeutics Corp. in a move that holds potential for the development of innovative drugs that treat cancerous tumors.
The acquisition of Hibiskus BioPharma was announced Sept. 3. Co-founded by Andre Bachmann of MSU's College of Hum . . .
A cancer research company co-founded by a Michigan State University professor was acquired by the New York biotechnology firm Lodo Therapeutics Corp. in a move that holds potential for the development of innovative drugs that treat cancerous tumors.
The acquisition of Hibiskus BioPharma was announced Sept. 3. Co-founded by Andre Bachmann of MSU's College of Hum . . .